eIF2Bδ Inhibitors are a class of chemical compounds that specifically target the δ subunit of eukaryotic initiation factor 2B (eIF2B), a critical regulator in the process of protein synthesis. eIF2B is a guanine nucleotide exchange factor (GEF) that plays a pivotal role in the initiation of translation by catalyzing the exchange of GDP for GTP on eIF2, a process essential for the formation of the translation initiation complex. The eIF2B complex is composed of five subunits (α, β, γ, δ, and ε), with each subunit contributing to the overall function and regulation of the complex. The δ subunit, in particular, is crucial for the structural stability and proper assembly of the eIF2B complex, as well as for the interaction with eIF2.
Inhibitors that target eIF2Bδ disrupt the normal function of eIF2B, leading to a decrease in its GEF activity. This disruption impacts the global regulation of protein synthesis within the cell, as the reduced activity of eIF2B results in decreased levels of active eIF2-GTP, ultimately leading to a slowdown in translation initiation. By inhibiting eIF2Bδ, researchers can investigate the broader regulatory mechanisms of protein synthesis and how cells respond to various stress conditions that affect translation. These inhibitors are valuable tools for studying the cellular responses to changes in translation rates, the role of eIF2B in maintaining proteostasis, and the intricate signaling pathways that regulate protein synthesis in response to environmental cues. Furthermore, eIF2Bδ inhibitors provide insights into the complex interplay between different subunits of the eIF2B complex and their individual contributions to the regulation of translation, making them an essential resource in the field of molecular biology and biochemistry.
SEE ALSO...
Items 11 to 18 of 18 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
DNA damage from Doxorubicin may cause the cell to prioritize DNA repair over regular functions, potentially suppressing RNAi machinery and decreasing eIF2C2 levels. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin′s inhibition of topoisomerase I can cause DNA damage, which might lead to a reduced focus on RNAi processes and subsequent lower eIF2C2 expression. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
By inhibiting Hsp90, Geldanamycin may destabilize proteins associated with RNAi, which could include a decrease in eIF2C2 stability or synthesis. | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
TAK-243 is a small molecule inhibitor of ubiquitin-activating enzyme (UAE) that indirectly affects EIF3ε by inhibiting protein translation. It has been studied for its potential as an anti-cancer therapy. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
A natural compound isolated from the plant Aglaia foveolata, known for its potent inhibition of EIF4AI. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Another natural compound found in several plants, such as the Aglaia genus, with strong EIF4AI inhibitory activity. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $193.00 $813.00 | ||
A synthetic EIF4AI inhibitor designed to disrupt the eIF4F complex, thereby inhibiting cap-dependent translation. | ||||||
eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 | 315706-13-9 | sc-202597 | 10 mg | $265.00 | 14 | |
A small molecule that disrupts the eIF4E-eIF4G interaction, thereby preventing translation initiation. | ||||||